- ICH GCP
- US Clinical Trials Registry
- Klinisk forsøg NCT01929577
A Study to Assess the Relative Bioavailability Between Two ASP015K Tablets and the Food Effect of a New Tablet in Healthy Adult Subjects
13. september 2013 opdateret af: Astellas Pharma Global Development, Inc.
A Phase 1, Single-Dose, Open-Label, 3-Period, Randomized Crossover Study to Assess the Relative Bioavailability Between Two ASP015K Tablet Formulations and the Food Effect on a New Tablet Formulation in Healthy Adult Subjects
The purpose of this study is to determine the relative bioavailability of ASP015K under fasting conditions after single-dose administration between a test-tablet formulation and a reference-tablet formulation.
This study will also evaluate the food effect on bioavailability of the test formulation, and evaluate the safety and tolerability after single-dose administration of the test- and reference-tablet formulations.
Studieoversigt
Status
Afsluttet
Betingelser
Intervention / Behandling
Undersøgelsestype
Interventionel
Tilmelding (Faktiske)
36
Fase
- Fase 1
Kontakter og lokationer
Dette afsnit indeholder kontaktoplysninger for dem, der udfører undersøgelsen, og oplysninger om, hvor denne undersøgelse udføres.
Studiesteder
-
-
Maryland
-
Baltimore, Maryland, Forenede Stater, 21225
- Parexel - Early Phase Clinical Unit
-
-
Deltagelseskriterier
Forskere leder efter personer, der passer til en bestemt beskrivelse, kaldet berettigelseskriterier. Nogle eksempler på disse kriterier er en persons generelle helbredstilstand eller tidligere behandlinger.
Berettigelseskriterier
Aldre berettiget til at studere
18 år til 55 år (Voksen)
Tager imod sunde frivillige
Ja
Køn, der er berettiget til at studere
Alle
Beskrivelse
Inclusion Criteria:
- Female subject must be of non-childbearing potential (i.e., post-menopausal [defined as at least 1 year without menses prior to screening], or documented surgically sterile or status post hysterectomy [at least 1 month prior to screening]).
- Female subject must have a negative pregnancy test at screening and day -1 of treatment period 1.
- Female subject must not donate ova starting at screening and throughout the study period, and for 90 days after the final study drug administration.
- Male subject and his female spouse/partner who is of childbearing potential must be using highly effective contraception consisting of two forms of birth control (one of which must be a barrier method) starting at screening and continue throughout the study period and for 90 days after final study drug administration.
- Male subject must not donate sperm starting at screening and throughout the study period and for 90 days after final study drug administration.
- Subject has a Body Mass Index (BMI) range of 18.5-32.0 kg/m2, inclusive, and must weigh at least 50 kg at screening.
Exclusion Criteria:
- Female subject who has been pregnant within 6 months before screening assessment or breast feeding within 3 months before screening.
- Subject has a known or suspected hypersensitivity to ASP015K, or any components of the formulation used.
- Subject has any clinically significant history of allergic conditions (including drug allergies, asthma, eczema, or anaphylactic reactions, but excluding untreated, asymptomatic, seasonal allergies at time of dosing).
- Subject has/had febrile illness or symptomatic, viral, bacterial (including upper respiratory infection), or fungal (non-cutaneous) infection within 1 week prior to first clinic check-in.
- Subject has used any prescribed or non-prescribed drugs (including vitamins, natural and herbal remedies, e.g., St. John's Wort) in the 2 weeks prior to study drug administration, with the exception of hormone replacement therapy (HRT), intermittent acetaminophen (to a maximum of 2 g/day).
- Subject has smoked or has used tobacco-containing products and nicotine or nicotine-containing products in the past six months prior to screening.
- Subject has a history of consuming more than 14 units of alcoholic beverages per week within 6 months prior to screening or has a history of alcoholism or drug/chemical substance abuse within past 2 years prior to screening (Note: one unit = 12 ounces of beer, 4 ounces of wine or 1 ounce of spirits) prior to day -1 of treatment period 1.
- Subject has had any significant blood loss, donated one unit (450 mL) of blood or more, or received a transfusion of any blood or blood products within 60 days or donated plasma within 7 days prior to clinic check-in on day -1 of treatment period 1.
- Subject has a positive test for hepatitis B surface antigen (HBsAg), anti-hepatitis A virus (HAV) (Immunoglobulin [Ig] M), anti-hepatitis C virus (HCV), hepatitis B core antibody, or anti-human immunodeficiency virus (HIV) type 1 or type 2 at screening.
- Subject has a positive tuberculosis (TB) skin test, Quantiferon Gold® test or T-SPOT® test at screening.
- Subject received any vaccine within 60 days prior to study drug administration.
- Subject has an absolute neutrophil count (ANC) < 2000 cells/mm3 or a creatine phosphokinase (CPK) > 1.5 x ULN at screening or day -1 of treatment period 1.
- Subject has had major gastrointestinal (GI) surgery or has a medical condition, which may inhibit the absorption and/or metabolism of study drug.
Studieplan
Dette afsnit indeholder detaljer om studieplanen, herunder hvordan undersøgelsen er designet, og hvad undersøgelsen måler.
Hvordan er undersøgelsen tilrettelagt?
Design detaljer
- Tildeling: Randomiseret
- Interventionel model: Crossover opgave
- Maskning: Ingen (Åben etiket)
Våben og indgreb
Deltagergruppe / Arm |
Intervention / Behandling |
---|---|
Eksperimentel: ASP015K Test Tablet - Fasting Conditions
ASP015K administered as a single tablet under fasting conditions.
|
oral tablet
|
Eksperimentel: ASP015K Reference Tablet - Fasting Conditions
ASP015K administered via multiple tablets under fasting conditions
|
oral tablet
|
Eksperimentel: ASP015K Test Tablet -Fed Conditions
ASP015K administered as a single tablet under fed conditions
|
oral tablet
|
Hvad måler undersøgelsen?
Primære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
---|---|---|
Pharmacokinetic parameter of ASP015K: Cmax
Tidsramme: Day 1-4 of each treatment period
|
Maximum Concentration (Cmax)
|
Day 1-4 of each treatment period
|
Pharmacokinetic parameter of ASP015K: AUClast
Tidsramme: Day 1-4 of each treatment period
|
Area Under the Curve from time zero to the last measurable time (AUClast)
|
Day 1-4 of each treatment period
|
Pharmacokinetic parameter of ASP015K: AUCinf
Tidsramme: Day 1-4 of each treatment period
|
Area Under the Curve from time zero extrapolated to infinity (AUCinf)
|
Day 1-4 of each treatment period
|
Sekundære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
---|---|---|
Composite of pharmacokinetic parameters of ASP015K: tmax, t1/2
Tidsramme: Day 1-4 of each treatment period
|
Time to Maximum Concentration (tmax), apparent terminal elimination half-life (t1/2)
|
Day 1-4 of each treatment period
|
Composite of pharmacokinetic parameters of ASP015K metabolites: Cmax, AUClast, AUCinf, tmax, t1/2
Tidsramme: Day 1-4 of each treatment period
|
Day 1-4 of each treatment period
|
|
Safety assessed by adverse events, clinical laboratory evaluations, 12-lead ECG measurements, physical examinations and vital sign measurements
Tidsramme: Up to Day 4 in each treatment period
|
Up to Day 4 in each treatment period
|
Samarbejdspartnere og efterforskere
Det er her, du vil finde personer og organisationer, der er involveret i denne undersøgelse.
Samarbejdspartnere
Datoer for undersøgelser
Disse datoer sporer fremskridtene for indsendelser af undersøgelsesrekord og resumeresultater til ClinicalTrials.gov. Studieregistreringer og rapporterede resultater gennemgås af National Library of Medicine (NLM) for at sikre, at de opfylder specifikke kvalitetskontrolstandarder, før de offentliggøres på den offentlige hjemmeside.
Studer store datoer
Studiestart
1. maj 2013
Primær færdiggørelse (Faktiske)
1. august 2013
Studieafslutning (Faktiske)
1. august 2013
Datoer for studieregistrering
Først indsendt
23. august 2013
Først indsendt, der opfyldte QC-kriterier
23. august 2013
Først opslået (Skøn)
28. august 2013
Opdateringer af undersøgelsesjournaler
Sidste opdatering sendt (Skøn)
16. september 2013
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
13. september 2013
Sidst verificeret
1. september 2013
Mere information
Begreber relateret til denne undersøgelse
Nøgleord
Yderligere relevante MeSH-vilkår
Andre undersøgelses-id-numre
- 015K-CL-PK09
Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .
Kliniske forsøg med ASP015K
-
Astellas Pharma Global Development, Inc.AfsluttetSunde frivillige | Farmakokinetik af ASP015K | Mad effektForenede Stater
-
Astellas Pharma IncAfsluttetPatienter med nedsat nyrefunktionJapan
-
Astellas Pharma China, Inc.Afsluttet
-
Astellas Pharma IncAfsluttetSunde emner | Farmakokinetik af ASP015KForenede Stater
-
Astellas Pharma IncAfsluttetSunde emner | Farmakodynamik | Farmakokinetik af ASP015KForenede Stater
-
Astellas Pharma IncAfsluttetSunde emner | Biotilgængelighed af ASP015K | Farmakokinetik af ASP015KForenede Stater
-
Astellas Pharma IncAfsluttetSunde emner | Farmakokinetik af ASP015KForenede Stater
-
Astellas Pharma IncAfsluttetGigt, reumatoidJapan, Korea, Republikken, Taiwan
-
Astellas Pharma Global Development, Inc.AfsluttetGigt, reumatoidForenede Stater, Polen, Tjekkiet, Bulgarien, Ungarn, Mexico
-
Astellas Pharma IncAfsluttetSunde emner | Biotilgængelighed af ASP015K | Farmakokinetik af ASP015KForenede Stater